Giredestrant vs Taragarestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Taragarestrant

Developed by InventisBio

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06954961 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGiredestrantTaragarestrant
PFS, median—Trial running · NCT06065748—Trial running · NCT06954961
OS, median—Trial running · NCT06065748—Trial running · NCT06954961
ORR—Trial running · NCT06065748—Trial running · NCT06954961
Clinical benefit rate—Trial running · NCT06065748—Trial running · NCT06954961

PFS, median

Giredestrant
—Trial running · NCT06065748
Taragarestrant
—Trial running · NCT06954961

OS, median

Giredestrant
—Trial running · NCT06065748
Taragarestrant
—Trial running · NCT06954961

ORR

Giredestrant
—Trial running · NCT06065748
Taragarestrant
—Trial running · NCT06954961

Clinical benefit rate

Giredestrant
—Trial running · NCT06065748
Taragarestrant
—Trial running · NCT06954961
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Taragarestrant: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Giredestrant: 3 of 4 rows · Taragarestrant: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGiredestrant
Dropout rate
8.7%a
NCT05659563 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT05659563 · Phase 2 · registry result, not featured evidence
Serious AEs
0%a
NCT05659563 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Ki67 -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wk
absolute change · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence
Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Taragarestrant's landscape